UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $55.00 price target on the stock. HC Wainwright also issued estimates for UroGen Pharma's Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.44) EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.51 EPS and FY2026 earnings at $0.27 EPS.

Several other brokerages also recently issued reports on URGN. D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Thursday, May 8th. Scotiabank initiated coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price objective on the stock. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective on the stock. Guggenheim restated a "buy" rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. Finally, The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Stock Performance

URGN stock traded down $0.02 during midday trading on Tuesday, hitting $9.85. 845,415 shares of the company traded hands, compared to its average volume of 547,508. UroGen Pharma has a twelve month low of $8.94 and a twelve month high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business has a 50 day simple moving average of $10.66 and a 200-day simple moving average of $10.94. The stock has a market capitalization of $454.15 million, a price-to-earnings ratio of -3.13 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. As a group, equities research analysts predict that UroGen Pharma will post -3.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. RTW Investments LP lifted its position in UroGen Pharma by 1.3% in the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after purchasing an additional 47,447 shares during the period. RA Capital Management L.P. bought a new position in UroGen Pharma in the first quarter worth $35,461,000. Vestal Point Capital LP lifted its position in UroGen Pharma by 32.1% in the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock worth $23,812,000 after purchasing an additional 522,957 shares during the period. Toronto Dominion Bank bought a new position in shares of UroGen Pharma during the fourth quarter valued at $18,628,000. Finally, Acorn Capital Advisors LLC bought a new position in shares of UroGen Pharma during the fourth quarter valued at $16,149,000. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.